Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) will likely be posting its Q4 2024 quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Spyre Therapeutics to post earnings of ($0.89) per share and revenue of $2.10 million for the quarter.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.08. On average, analysts expect Spyre Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Spyre Therapeutics Trading Up 7.2 %
Shares of SYRE stock traded up $1.33 on Friday, hitting $19.70. 651,522 shares of the stock were exchanged, compared to its average volume of 601,152. Spyre Therapeutics has a fifty-two week low of $18.26 and a fifty-two week high of $47.97. The business has a 50-day moving average of $22.36 and a 200 day moving average of $26.81. The firm has a market capitalization of $1.01 billion, a P/E ratio of -2.64 and a beta of 2.85.
Analyst Ratings Changes
A number of research firms recently weighed in on SYRE. Wedbush reaffirmed an "outperform" rating and issued a $65.00 target price on shares of Spyre Therapeutics in a research report on Monday, January 13th. Robert W. Baird upped their target price on Spyre Therapeutics from $50.00 to $65.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. Finally, The Goldman Sachs Group upgraded Spyre Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 18th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $54.83.
Read Our Latest Stock Analysis on SYRE
About Spyre Therapeutics
(
Get Free Report)
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Read More
Before you consider Spyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.
While Spyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
